• Journal of Pharmaceutical Investigation
• /
• 제39권4호
• /
• pp.299-307
• /
• 2009

Data exclusivity is one of the most important intellectual property rights of pharmaceuticals. During data exclusivity period, third parties are prohibited from relying on the data which the original company has submitted to regulatory authority for drug application. I investigated data exclusivity systems for pharmaceuticals in the US, EU, Canada and Korea. New chemical entities were usually given the longest periods of data exclusivity compared to drugs with new indication or new formulation, although the protection periods varied by country. For new drugs to be entitled to a data exclusivity, strict conditions should be met. Data exclusivity has also been provided as an incentive to promote clinical investigation and drug development for pediatric population or orphan diseases. In Korea, data exclusivity was adopted in 1995 as an additive provision to "drug re-examination" which is to investigate post-marketing safety information of new drugs. It was introduced with few discussion on the purposes or effects of data exclusivity on pharmaceutical industry and pharmaceutical market in this country. I found that Korea's data exclusivity system falls short of considerations on valuing innovation of pharmaceutical research. It is necessary to improve data exclusivity system in order to promote innovative pharmaceutical development and to balance intellectual property rights protection and access to drugs in this country.

• 무역상무연구
• /
• 제48권
• /
• pp.101-125
• /
• 2010

CEPA(Comprehensive Economic Partnership Agreement, hereinafter CEPA) between India and Korea may influence some changes on Korean pharmaceutical industry which shows less competitive advantages than Indian industry in many regards. So the purpose of this paper remains on suggesting the way of enhancing international competitiveness for Korean industry on the basis of double diamond model. Through the comprehensive and deep analysis, our findings on recommendable business strategies for Korea are as follows ; in terms of factor conditions, first, cooperative strategy in R&D for developing generics will be required. Second, Introduction of CMO business can be considered. In terms of demand condition, Korean firms should find out the chance for demand creation in Indian market which has future market potential and American market exploration, as soon as possible. With regards to strategy, structure and competition, trying M&A with leading Indian companies and utilizing well organized medical professionals in India will be considered. In the points of related and supportive parts, lastly, Korean government should try to make so called "National Strategic R&D committee" for pharmaceuticals and bring u-healthcare service to Korea in the first place. If Korean pharmaceutical industry implement above-mentioned strategies, CEPA can be turned into business opportunities from the crisis. As a result, Korean firms shall have more powerful global competitiveness eventually.

• The Journal of Asian Finance, Economics and Business
• /
• 제8권4호
• /
• pp.735-740
• /
• 2021

The purpose of this study is to assess how accounting conservatism is practiced in the Jordanian pharmaceuticals and medical industry. It assesses the association between accounting conservatism and intellectual capital (IC) in this industry. This study measures IC performance using the market price per share less book value. Accounting conservatism is measured using the book-to-price ratio, and the data was collected from company annual reports and the Amman Stock Exchange (ASE) website. The data was collected for the period of six years (2014 to 2019). The sample was made up of four companies in the industry listed in the ASE. The data was analyzed using the SPSS program though the ordinary least squares regression model to assess how accounting conservatism is associated with IC. The findings indicate a negative association with companies having higher IC performance and reporting lower accounting conservatism. IC is applied more in these companies, although it might be lower than in other companies in other sectors. This study provides empirical evidence on how IC is applied in the industry and how it might be negatively associated with accounting conservatism. Findings indicate the need for more effective policies to promote recognition of intangible assets in the sector.

• 산경연구논집
• /
• 제3권1호
• /
• pp.25-29
• /
• 2012

The purpose of this study is to examine the development of the pharmaceutical distribution industry. The pharmaceutical industry is are expected to suffer a heavy blow when the Free Trade Agreement (FTA) is introduced, despite its best efforts. Therefore, adequate solutions must be found. Section II introduces the Korean pharmaceutical distribution system and its current situation; Section III explores the distribution system's strengths and weaknesses. Section IV, identifies the problem and possible solutions for the Korean pharmaceutical distribution system; Section V summarizes and concludes this paper and acknowledges its limitations. Finally, this paper has a clear limitation. The lack of objective information and scientific analysis due to the data being based on interviews with company representatives is its most significant shortcoming. However, it offers implications for new directions for future research.

• STI Policy Review
• /
• 제8권1호
• /
• pp.87-112
• /
• 2017

This study analyzes patenting practices in the pharmaceutical industry and the impacts of sequential innovation. The main argument of the research is that strategic patenting is common in the pharmaceutical sector and it is legal within the context of patent law. However, when these practices have negative effects on the competition process post-grant, the practices that are legal under patent law may come into conflict with antitrust laws, which are not applied. The study brings into question whether sequential patenting practices characteristic of the pharmaceutical industry encourage or discourage innovation, and moreover, the overall functionality of the patent system. Ultimately, the functionality of the patent system creates market incentives that neglect consumer, i.e., patient, welfare; potential solutions to deal with the shortcomings are discussed.

• International Journal of Oral Biology
• /
• 제43권1호
• /
• pp.1-3
• /
• 2018

Blockchain is at the center of attention recently and it is expected to have a huge impact on healthcare industry including dentistry as well. Blockchain is a fundamental technology behind Bitcoin and itis all about decentralization, security, reliability, and transparency. These characteristics of the technology empower it to disrupt the current healthcare industry in innumerable practices such as supply chain management in pharmaceuticals to prevent the counterfeited medicine, clinical trials to guarantee transparency, healthcare information exchanges or personal health record systems to ensure data integrity and interoperability, etc. It will surely revolutionize the way the current healthcare system works; from provider-oriented to patient-centered. Hence, it is time to seriously consider how we could be a part of this blockchain revolution in dentistry.

• Journal of Plant Biotechnology
• /
• 제5권2호
• /
• pp.69-77
• /
• 2003

The ornamental industry encompasses cut flower, pot plant, turfgrass and nursery stock production and is an important part of the agricultural sector. As internationally traded commodities, cut flowers and plants are an integral part of the economy of a number of developing countries in South America, the Caribbean and Africa. Genetic modification (GM) is a tool with great potential to the ornamental horticulture industry. The rapid progress in our knowledge of plant molecular biology can accelerate the breeding ornamental plants using recombinant DNA technology techniques. Not only is there the possibility of creating new, novel products the driver of the industry but also the potential to develop varieties requiring less chemical and energy inputs. As an important non-food agricultural sector the use of genetically modified (GM) ornamental crops may also be ideal for the intensive farming necessary to generate pharmaceuticals and other useful products in GM plants. To date, there are only a few ornamental GM products in development and only one, a carnation genetically modified for flower colour, in the marketplace. International Flower Developments, a joint venture between Florigene Ltd. in Australia and Suntory Ltd. of Japan, developed the GM carnations. These flowers are currently on sale in USA, Japan and Australia. The research, development and commercialization of these products are summarized. The long term prospects for ornamental GM products, like food crops, will be determined by the regulatory environment, and the acceptance of GM products in the marketplace. These critical factors will be analysed in the context of the current legislative environment, and likely public and industry opinion towards ornamental genetically modified organisms (GMO's).

• 한국식물생명공학회:학술대회논문집
• /
• 한국식물생명공학회 2003년도 식물바이오벤처 페스티발
• /
• pp.39-48
• /
• 2003

The ornamental industry encompasses cut flower, pot plant, turfgrass and nursery stock production and is an important part of the agricultural sector. As internationally traded commodities, cut flowers and plants are an integral part of the economy of a number of developing countries in South America, the Caribbean and Africa. Genetic modification (GM) is a tool with great potential to the ornamental horticulture industry. The rapid progress in our knowledge of plant molecular biology can accelerate the breeding ornamental plants using recombinant DNA technology techniques. Not only is there the possibility of creating new, novel products the driver of the industry but also the potential to develop varieties requiring less chemical and energy inputs. As an important non-food agricultural sector the use of genetically modified (GM) ornamental crops may also be ideal for the intensive farming necessary to generate pharmaceuticals and other useful products in GM plants. To date, there are only a few ornamental GM products in development and only one, a carnation genetically modified for flower colour, in the marketplace. International Flower Developments, a joint venture between Florigene Ltd. in Australia and Suntory Ltd.of Japan, developed the GM carnations. These flowers are currently on sale in USA, Japan and Australia. The research, development and commercialisation of these products are summarised. The long term prospects for ornamental GM products, like food crops, will be determined by the regulatory environment, and the acceptance of GM products in the marketplace. These critical factors will be analysed in the context of the current legislative environment, and likely public and industry opinion towards ornamental genetically modified organisms (GMO's).

• Asian Journal of Innovation and Policy
• /
• 제12권1호
• /
• pp.054-074
• /
• 2023

With the advent of the '4th Industrial Revolution', digitalization using AI (Artificial Intelligence), big data, IoT (Internet of Things), cloud computing and mobile is accelerating across all industries and global companies have fundamentally reorganized customer experiences, business models, and operations centering on digital transformation. Business innovation drives productivity improvement, process simplification, price, competitiveness and sustainable expansion. Whether digital transformation will be necessary for the current industrial environment is no longer important, and how quickly companies achieve digitalization has emerged as the utmost crucial element in industrial continuity. As non-face-to-face and remote technologies have begun in earnest, and accelerated in the pharmaceutical industry. They are looking for ways to provide value, generate profits, improve efficiency, and sustain the future. Compared to other industries, the pharmaceutical-related sectors have shown high interest in digital transformation especially to reduce costs and meet the challenge of delivering products during the pandemic environment.

• 한국임상약학회지
• /
• 제27권4호
• /
• pp.238-249
• /
• 2017

Background: Currently establishment of public pharmaceutical companies became an issue for securing stable supply of national essential drugs in order to respond appropriately to national public health crisis. Pharmacy students as future pharmacists need to be interested in drug related issues under the discussion in our society. This study aimed to investigate perceptions of pharmacy students on the national drug supply strategy through public pharmaceutical companies. Methods: A 20-items questionnaire designed for this study was used. Pharmacy students nationwide were enrolled in July 2017. They responded to questions through on-line survey program. Data were analyzed descriptively. Results: 160 students from 26 pharmacy schools participated. 5th and 6th grade students accounted for two-thirds, and one third aspired future jobs in pharmaceutical industry. Among responders, 71.3% was unaware of current national essential drugs, 52.5% did not know the Rare and Essential Drug Center, and 91.9% was unaware of the legislation on the supply and management of essential drugs. 82.5% favored the establishment of public pharmaceutical companies. 80.6% agreed that government should intervene in pharmaceutical market for ensuring drug accessibilities, 73.8% agreed that public pharmaceutical companies make possible to reach a goal of stable supply of pharmaceuticals, and 85.1% agreed that active compulsory license by public pharmaceutical companies is necessary. Conclusion: We found that pharmacy students recognized the need for governmental control to achieve social values of pharmaceuticals. More attention and participation of the pharmacy students as well as pharmacists in the process of national debate on public pharmaceutical companies are expected.